Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient.
A 38-year-old women underwent first cadaver kidney transplantation. Her panel reactive antibody was 0%, and she had never previously been transfused nor pregnant. She received induction therapy with antithymoglobulin (ATG) as standard protocol and maintained on immunosuppressive treatment of cyclosporine A, mycophenolate mofetil (MMF), and prednisone. Nine months after transplantation, she presented with anorexia, asthenia and weight loss. Cutaneous Kaposi's sarcoma and a Hodgkin disease were diagnosed. MMF was discontinued and cyclosporine A was switched to sirolimus. She also received a poly-chemotherapy associated with 4 courses of rituximab. Twelve months later, the patient had normal graft function and both malignancies were in complete remission.
Yaich
S
S
Department of Nephrology and Renal Transplantation, University Hospital, Sfax-Jadida, Sfax, Tunisia.
Zagdane
S
S
Charfeddine
K
K
Hssairi
D
D
Hachicha
J
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D009378:Neoplasms, Multiple Primary; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents